Homebiotech

biotech

biotech

Base to Base biotech podcast 56: GRIN genes and relapsing MS

Jim Cornall - April 24, 2026

biotech

Positive first-in-human data for IVF-related embryo implantation failure treatment

Jim Cornall - April 23, 2026

biotech

New company plans to replace daily injections with implant

Jim Cornall - April 23, 2026

biotech

UCB adds epilepsy drug through Neurona Therapeutics acquisition

Jim Cornall - April 23, 2026

biotech

Anti-cancer drug gets phase I FDA trials approval

Jim Cornall - March 12, 2026

biotech

New mass spec platform launched

Jim Cornall - March 12, 2026

biotech

Approval for prostate cancer treatment

Jim Cornall - March 12, 2026

biotech

Approval for atopic dermatitis treatment

Jim Cornall - March 11, 2026

biotech

FDA Breakthrough Therapy Designation for Glanzmann Thrombasthenia drug

Jim Cornall - March 11, 2026

biotech

New company targets dry eye disease with first-in-class therapy

Jim Cornall - March 11, 2026

biotech

Collaboration to advance novel combination therapy for glioblastoma

Jim Cornall - March 10, 2026

biotech

Study shows AI boosts breast cancer detection by more than 10 percent

Jim Cornall - March 10, 2026

1...91011...72 Page 10 of 72

Stay Connected

- Advertisement -

spot_img

Latest Articles

biotech

Base to Base biotech podcast 56: GRIN genes and relapsing MS

Jim Cornall - April 24, 2026 0

This week, our conversations are with Bruce Leuchter, co-founder, president, CEO of Neurvati Neurosciences and GRIN Therapeutics; and Daniel Vitt, CEO of Immunic. Base to...

Positive first-in-human data for IVF-related embryo implantation failure treatment

biotech Jim Cornall - April 23, 2026 0

New company plans to replace daily injections with implant

biotech Jim Cornall - April 23, 2026 0

UCB adds epilepsy drug through Neurona Therapeutics acquisition

biotech Jim Cornall - April 23, 2026 0

Mechanism ‘opens new era’ for targeted cancer therapy

biotech Jim Cornall - April 22, 2026 0